Aiphi Nguyen, PharmD, CEO

​Dr. Aiphi Nguyen has more than 17 years combined experience within the pharmaceutical and financial industry. She held various positions in marketing and sales at Bristol Myers Squibb in pediatrics with the responsibility of noticeable launch in orphan diseases or allergy field in France. Then she steered in the investment bank sector where she served as a business and financial analyst consultant engaged in various deals valuation mandates in the life sciences sector. Prior to Skymab, she had on her credit the creation of two successful companies (Etsi communication and dixhuit Production).

​Dr. Aiphi Nguyen holds a Doctorate in Pharmacy of the University Claude Bernard, a MBA of IAE (Institut d’Administration des Entreprises from Sorbonne University), a master of science in Finance of ESCP Europe and Challenge Plus of HEC Startup Program.

Caroline Mouline, PhD, R&D projects manager

Dr Caroline Mouline has more than 12 years experience in preclinical studies carried out on small molecules and therapeutic antibodies as Research Engineer. She conducted in-depth  research on small molecule derived from algae for the treatment of blood diseases with Kercells Biosciences. Prior joining Skymab, she gained extensive knowledge in immunotherapy in the laboratory of the University of Tours dedicated to therapeutics antibodies working on the induction of toloerogenic dendritic cells to treat transplant rejection.

Dr Caroline Mouline obtained her PhD in 2010 under the direction of Dr Jean-Claude Scimeca at the Nice University.

Peter Hudson, PhD, ADC expert advisor

Adj. Prof. Peter Hudson is a renowned scientist, ADC expert and inventor in the commercial development of immunotherapeutic products. Peter was Director of the Victorian Cancer Biologics (VCB) consortium in Australia and led the first-in-man clinical trial of a cancer-targeting diabody (2010-2018). Dr. Hudson is a prolific entrepreneur, having co-founded four immunotherapy companies Evogenix. (2001), Avipep (2005), CarTherics (2015), IsoClide Medical (2017) and has been an advisor to many international biotechnology companies including Affitech, ArGenX, Merus, CSL and Selexis.

Peter is currently an Adjunct Professor at the University of Queensland and formerly led large research teams as Chief Research Scientist in CSIRO (Australia’s premier science agency, 1984-2007) and as Scientific Director of the Cooperative Research Centre (CRC) for Diagnostics (1992-2007) and as BDM in the CRC for Mental Health (2009-2012). Peter earned his Ph.D. from the University of Cambridge (UK, 1980) for research at the renowned MRC Laboratory of Molecular Biology. He was later elected to the Australian Academy of Technological Sciences and has been awarded the Boehringer, AMRAD and CSIRO Chairman’s Medals.

Peter Suenaert, MD, PhD, acting as CMO

Peter Suenaert, MD, PhD, is Clinical Advisor to Skymab with almost 30 years of experience including clinical practice and global development activities in oncology in the pharmaceutical and biotech industry.  Currently Peter provides strategic, management and hands-on clinical development services in life sciences to biotech companies in the field of oncology and microbial R&D in EU and USA through his company SparkClin BV.

Previously, he served as Vice-President Global Clinical Development at AgenTus Therapeutics (BE/US) developing clinical strategy and successfully implenting the first-in human clinical trial with iNKT cell therapy in blood cancers in the US.  Prior to this position, from 2016 – 2019, he worked as Chief Medical Officer at Immunicum AB developing a clinical team and bringing the allogeneic cell therapy asset to proof of concept in metastatic renal cell cancer which received RMAT designation from FDA, apart from conducting trials in other indications that received fast track and/or orphan drug designations in US or EU.  Before he was Global Oncology Lead at Glenmark Pharma (Immunotherapeutics, UK) developing the clinical strategy and successfully starting a first-in human trial with bispecific antibody.  Prior this position, he was Medical Director Early Clinical Development at GSK Bio (Cancer Immunotherapeutics, BE)) from 2011 till 2014 where he managed several clinical trials (translational and ph1/2) with new cancer vaccines mostly in the field of melanoma up to PoC.  In 2007 Peter started his pharma career at Amgen as Medical Advisor in Belgium and Senior Medical Scientist Haematology/Oncology Late Phase Global Development at Amgen (US/UK) contributing to the approval of the monoclonal anti-RANK-ligan antibody, denosumab, by FDA and EMA in several cancer indications.  He is a board-certified medical doctor in Gastroenterology, qualified in Digestive Oncology and has a PhD in Medical Sciences from Leuven University, Belgium. He completed a post-doc at McGill University Health Center, Canada, and at Institut Gustave Roussy, France, and was on staff as Clinical Head Digestive Oncology at the University Hospital Antwerp before joining the pharmaceutical industry.